<DOC>
	<DOCNO>NCT01348737</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability blood concentration AZD3839 follow oral administration single dose healthy men woman non-childbearing potential</brief_summary>
	<brief_title>Assessment Safety , Tolerability Blood Concentrations Single Doses AZD3839 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy male female volunteer nonchildbearing potential age 18 55 year ( inclusive ) suitable vein cannulation repeat venipuncture Have body mass index ( BMI ) 19 30 kg/m2 ( inclusive ) weigh 50 kg 100 kg ( inclusive ) Creatinine clearance normal range ( &gt; 80 mL/min estimate accord CockroftGault ) Healthy volunteer serum potassium concentration â‰¥3.8 mmol/L screening ( Visit 1 ) admission study centre ( Day 1 ) Clinically normal finding physical examination relation age , judge Investigator History clinically significant disease disorder , opinion Investigator , may either put healthy volunteer risk participation study , influence result healthy volunteer 's ability participate study History psychotic disorder amongst first degree relative Significant orthostatic reaction enrolment judge Investigator Prolonged QTcF great 450 msec shorten QTcF le 340 msec family history long QT syndrome sudden death Healthy volunteer vegetarian/lactose intolerant ( exclusion criterion applicable healthy volunteer participate Part 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>AZD3839</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>